Grail released new PATHFINDER2 data from a 36,000‑participant U.S. study showing the Galleri multi‑cancer screening test detected 40.4% of cancers in participants followed for a year, with increased detection of cancers not covered by standard screening. Crucially, the positive predictive value (PPV) for positive tests improved to about 62% in the studied cohorts — a step up from prior results. The dataset strengthens Grail’s regulatory case as the company readies or finalizes submissions, but experts note ongoing questions about downstream diagnostic pathways and population‑level impact.